Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.51M | -1.64M | -1.59M | -1.16M | -1.20M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 550.50K | 553.70K | 559.60K | 234.40K | 225.30K |
| Change in Net Operating Assets | -101.40K | 320.80K | 208.30K | 90.80K | 253.80K |
| Cash from Operations | -1.06M | -761.30K | -824.90K | -833.30K | -724.80K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.02M | 1.02M | 1.02M | 1.43M | 500.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 758.10K | 685.70K | 2.60K | 2.60K | 2.60K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -88.00K | -88.00K | -88.00K | -95.60K | -31.40K |
| Cash from Financing | 1.20M | 1.15M | 658.30K | 949.60K | 344.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.20K | 389.40K | -166.50K | 116.40K | -380.70K |